| Metric | Value (₹ Cr) | Q2 FY26 | Q3 FY25 |
|---|---|---|---|
| Revenue | 233.10 | 4.8% | 19.5% |
| Total Income | 237.67 | 5.1% | 19.4% |
| Expenditure | 217.70 | 7.5% | 21.8% |
| PBT | 19.97 | 15.3% | 1.8% |
| Net Profit | 15.00 | 15.7% | 3.7% |
| OPM | 10.46% | 2.38pp | 6.44pp |
| NPM | 6.31% | 1.56pp | 1.51pp |
| EPS | 7.12 | 16.0% | 4.4% |
Windlas Biotech Ltd Announces Q3 and Nine Months Results for 2025, Reports Profit of 797.58 Million INR
05 Feb 2026 · 5 Feb, 6:03 pm
Summary
The Board of Directors of Windlas Biotech Ltd approved the Unaudited Standalone and Consolidated Financial Results for the quarter and nine months ended December 31, 2025. The meeting commenced at 4.00 P.M. and concluded at 5.20 P.M. The financial results have been reviewed by J.C. BHALLA & CO. CHARTERED ACCOUNTANTS.
Key Highlights
- 1
Profit of 797.58 Million INR for the quarter and nine months ended December 31, 2025
- 2
The financial results have been reviewed by J.C. BHALLA & CO. CHARTERED ACCOUNTANTS
- 3
The meeting of the Board of Directors commenced at 4.00 P.M. and concluded at 5.20 P.M.
Informational and educational content only. Not investment advice.